AbbVie (ABBV) reported results from its Phase 2 study of Rova-T Thursday morning and has decided that it will not seek accelerated approval for the drug in third-line relapsed/refractory small cell lung cancer.
from RTT - Before the Bell http://ift.tt/2HZdJBN
via IFTTT
No comments:
Post a Comment